A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 0
- Population
- ALL · 50 Years
- Duration
- 2021-05-31 to 2025-05-31
- Intervention
- brolucizumab
- Comparator
- Not reported
- Outcomes measured
- The proportion (%) of patients switched from aflibercept 2 mg to brolucizumab 6mg that were able to successfully extend…; Mean maximum interval (number of weeks) of patients at week 104 — Up to 104 weeks; The % of patients switched from aflibercept 2 mg to brolucizumab 6mg that were able to extend their dosing interval at…; The % of patients switched from aflibercept 2 mg to brolucizumab 6mg that were able to maintain or extend their dosing…; Mean interval (number of weeks) of patients after switch reached at any given time point at week 52 and 104 — up to 104…; Mean change in Best Corrected Visual Acuity (BCVA) Early Treatment Diabetic Retinopathy Study (EDTRS letters) from base…; The % of patients with a change in BCVA (EDTRS letters) of 5, 10, 15 letters or more from baseline to week 52, and 104…; The % of patients with any intraretinal fluid (IRF) and/or subretinal fluid (SRF) at baseline, weeks 52, and 104 — up t…; Incidence of ocular (e.g., intraocular infection) and non-ocular adverse events, vital signs up to week 52, and 104 — u…; Mean change from baseline in central subfield foveal thickness (CSFT) — at weeks 52, 104; The % of patients with pigment epithelial detachment (PED) — at baseline, weeks 52, 104
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.